Author:
Fukuda Yasunari,Yamada Daisaku,Eguchi Hidetoshi,Hata Tomoki,Iwagami Yoshifumi,Noda Takehiro,Asaoka Tadafumi,Kawamoto Koichi,Gotoh Kunihito,Kobayashi Shogo,Takeda Yutaka,Tanemura Masahiro,Mori Masaki,Doki Yuichiro
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Cancer.net. Pancreatic cancer: Statistics.
http://www.cancer.net/cancer-types/pancreatic-cancer/statistics
. Accessed 26 Feb 2017.
2. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors, 7th edn. Hoboken, NJ: John Wiley & Sons 2009.
3. Han SH, Heo JS, Choi SH, et al. Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection. J Surg. 2017. DOI:
10.1016/j.ijsu.2017.02.007
.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
5. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-703.
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献